Transderm Scop (scopolamine) Transdermal System, 1.5 mg, 24 patches Multi pack, Rx only, Marketed...
FDA Drug Recall #D-0133-2017 — Class II — August 24, 2016
Recall Summary
| Recall Number | D-0133-2017 |
| Classification | Class II — Moderate risk |
| Date Initiated | August 24, 2016 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Sandoz Inc |
| Location | Princeton, NJ |
| Product Type | Drugs |
| Quantity | 42,740 cartons (24 count carton from 7 total lots) |
Product Description
Transderm Scop (scopolamine) Transdermal System, 1.5 mg, 24 patches Multi pack, Rx only, Marketed by Baxter Healthcare Cop/Novartis, Deerfield, IL 60015, Manufactured by:Alza Corporation, Vacaville, CA 95688 for Novartis Consumer Health Inc., Parsippany, NJ 07054
Reason for Recall
Defective Delivery System; reports of damaged product that may alter the predicted release of scopolamine following transdermal application.
Distribution Pattern
TN
Lot / Code Information
NDC 10019-553-02 (24 ct. carton) and NDC 10019-553-88 (patch); Lot #'s FV5908 and FX1520 both with expiry 06/2018; GB4910 and GC4210 both with expiry 09/2018; GE1927 with expiry 12/2018; GF7017 with expiry 01/2019 and GH8065 with expiry 02/2019.
Other Recalls from Sandoz Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0651-2025 | Class II | Cyclophosphamide Injection 500 mg/5 mL (100 mg/... | Sep 5, 2025 |
| D-0626-2025 | Class II | Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic ... | Aug 13, 2025 |
| D-0569-2025 | Class I | Cefazolin for Injection, USP, 1 gram per vial, ... | Jun 27, 2025 |
| D-0570-2025 | Class I | Buffered Penicillin G Potassium for Injection, ... | Jun 27, 2025 |
| D-0286-2022 | Class I | Enoxaparin Sodium Injection, USP, 40 mg/0.4 mL,... | Nov 17, 2021 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.